Australia's Unique Device Identification (UDI) requirements began on 1 July 2026, starting with Class III and IIb devices. Here's what medical device sponsors must do — and by when.

A new obligation that's already live

As of 1 July 2026, medical devices supplied in Australia are subject to Unique Device Identification (UDI) requirements. This isn't a proposal on the horizon — for the first group of devices, the clock has already started. If you sponsor medical devices, UDI adds new labelling and data-submission duties on top of your existing ARTG obligations, and they phase in by device class over the next few years.

The short version: every affected device needs a standardised identifier on its label, and its data lodged in a national database. It's a traceability system, and compliance is not optional.

What UDI actually is

UDI gives each device a consistent, machine-readable identity so it can be tracked accurately through the supply chain — particularly during recalls and safety actions. In practice it has two parts:

  • A UDI carrier — the code (for example a barcode or data matrix) applied to the device label and relevant packaging.
  • A data record — the UDI-Device Identifier (UDI-DI) and associated information, submitted to the Australian UDI Database (AusUDID) and linked to your product's ARTG entry.

Together these let the TGA, health professionals and industry identify exactly what a device is and trace it reliably.

The phased timeline — higher-risk devices first

UDI is rolling out by risk class, starting at the top:

  • Class III and Class IIb (higher-risk devices) — from 1 July 2026 (now in effect)
  • Class IIa — from 1 July 2027
  • Class Is and higher-risk IVDs — from 1 July 2028

So if you sponsor Class III or IIb devices, you are in the first wave and the requirements apply now. If your devices sit in the later groups, the sensible move is to start preparing rather than wait — the work involved isn't something you switch on overnight.

What sponsors actually have to do

For an affected device, the core obligations are:

  • Apply the UDI carrier to the device label and relevant packaging.
  • Submit the UDI-DI and associated data to AusUDID within 30 days of the device's next supply in Australia.
  • Link the data to the ARTG ID, and keep the record accurate and up to date as things change.

That sounds straightforward, but each step has practical depth — obtaining UDIs through an approved issuing agency, getting label artwork right, and managing the data submission and ongoing updates all take setup and process.

Where the effort really sits

The parts that catch sponsors out tend to be the mechanics rather than the concept:

  • Assigning UDIs through an accredited issuing agency and applying the correct carrier format.
  • Label and packaging changes — updating artwork and print processes to carry the UDI, and coordinating that with manufacturers overseas.
  • Data management — populating AusUDID accurately, linking to the right ARTG entries, and keeping records current as devices and details change.
  • Working out scope and timing — confirming which of your devices fall into which wave, so nothing is missed and nothing is done prematurely.

Who should act now

You should be moving if you:

  • Sponsor Class III or Class IIb devices — the requirements are live as of 1 July 2026.
  • Sponsor Class IIa, Class Is or higher-risk IVDs — your deadlines are 2027–2028, and preparation should be underway.
  • Are unsure which of your devices are affected, or when — that mapping is the first thing to get right.

How Engel Hellyer & Partners can help

UDI is exactly the kind of obligation that's manageable with a clear plan and painful without one. As trusted TGA medical device consultants, we help sponsors work out which devices are caught in each wave, get the UDI carriers and labelling right, and set up accurate, on-time submissions to AusUDID that stay linked to your ARTG entries.

If you sponsor medical devices in Australia and want to be sure your UDI obligations are covered — starting with the Class III and IIb devices already in scope — we're happy to take a look.

This article is general information only and does not constitute regulatory advice for any specific product. Requirements and timeframes change; confirm the current position before acting.

Further reading

Primary guidance from the Therapeutic Goods Administration:

‍

Written by 
Dr Renée Badenhop
Renee received a Bachelor of Science at the University of Sydney and a Bachelor of Science (Honours) at Macquarie University and in 1997 she was awarded a PhD (Medicine) at the University of NSW. In 2005 she completed a Master’s Degree in Industrial Property at the University of Technology. Renee has been Director at Engel Hellyer & Partners since 2013.